Clomiphene (Clomid)

Clomiphene keeps getting lumped in with peptides and “research chemicals” in fitness circles, but it is neither. It is a selective estrogen receptor modulator (a drug that turns the body’s estrogen signals up in some tissues and down in others) — a small-molecule oral drug in the same chemical family as tamoxifen. That single fact explains how it works and what it is actually good for. It has a real, FDA-approved medical job in women, a well-studied off-label use for raising testosterone in men, and a known list of risks — including vision problems the FDA label warns may be permanent.

What it is

Clomiphene citrate is a nonsteroidal SERM in the triphenylethylene class (a chemical group it shares with tamoxifen and toremifene). You take it by mouth. The version sold in pharmacies isn’t one single molecule — it’s a blend of two mirror-image forms (isomers): roughly 62% enclomiphene, the part that mostly blocks estrogen, and about 38% zuclomiphene, a longer-lasting form that acts partly like estrogen. Zuclomiphene sticks around a long time — more than a month — so it can build up over repeated cycles. (Enclomiphene is the (E)-isomer and zuclomiphene the (Z)-isomer. The older cis/trans names for these got flipped in the literature after 1976 X-ray crystallography work, which is why this profile avoids them.)

Here’s how it works. Clomiphene parks itself on estrogen receptors (the docking sites that estrogen normally uses) in the hypothalamus and pituitary — two control centers in the brain. Normally estrogen tells the brain to ease off; clomiphene blocks that “ease off” message. The brain reads this as low estrogen and pumps out more GnRH (gonadotropin-releasing hormone, the signal that kicks off the whole chain). That in turn raises two pituitary hormones, LH and FSH. In women, this drives the ovaries to develop a follicle and release an egg (ovulation). In men, the extra LH and FSH push the testes to make more of their own testosterone and to keep sperm production going — which is exactly why it gets used off-label as an alternative to testosterone replacement in men who want to stay fertile.

The claims

The official, FDA-approved use is narrow: triggering ovulation in women with ovulation problems who are trying to get pregnant. Even then, doctors aren’t supposed to keep cycling it much beyond about six cycles. Clomiphene is not FDA-approved for men at all.

The off-label use in men — for secondary (hypogonadotropic) hypogonadism, meaning low testosterone caused by weak brain signaling rather than a testicular problem — is where most of the interest comes from, especially among men who want to protect their fertility. Taking testosterone from the outside shuts down the body’s own hormone chain (the HPG axis) and sperm production, so clomiphene is pitched as a way to raise your own testosterone without flipping that switch off. (One thing worth flagging: the NCBI StatPearls chapter loosely says clomiphene is “approved for male spermatogenesis induction.” That contradicts the actual FDA label, which limits the approved use to women. The label is the authority here.)

In athletics and bodybuilding, clomiphene gets used as an “anti-estrogen,” as a way to try to restart the body’s own testosterone after a run of anabolic-androgenic steroids (by pushing LH and FSH back up), and to fight off estrogen-related side effects. This profile deliberately gives no doses, cycles, stacks, or post-cycle plans.

What the evidence actually shows

For raising testosterone in men, the human evidence is reasonably strong and consistent.

• Huijben et al. 2022 (Andrology), systematic review and meta-analysis: 19 studies (4 RCTs plus 15 observational), 1,642 patients. Total testosterone rose during clomiphene treatment, with a pooled standardized increase of about 2.60 (95% CI 1.82–3.38). The authors concluded clomiphene effectively raises testosterone but called for more high-quality RCTs.
• Hohl et al. 2025 (Archives of Endocrinology and Metabolism), RCT-only meta-analysis of clomiphene/enclomiphene: SERM therapy significantly increased total testosterone versus placebo (mean difference 273.76 ng/dL; 95% CI 191.87–355.66) and showed no significant difference versus testosterone gel (MD 5.41 ng/dL; p=0.83). The evidence was rated moderate quality (wide confidence intervals and heterogeneity) and was underpowered for safety endpoints. Notably, SERMs preserved LH, FSH, and spermatogenesis better than testosterone gel.

The honest bottom line: there is reasonably consistent human evidence that clomiphene raises testosterone in the blood and, unlike testosterone taken from the outside, can keep sperm production going. But we still don’t have much long-term data on real-world health outcomes or safety, and male use is not FDA-approved.

Legal and regulatory status

In the United States, clomiphene (Clomid) is a prescription drug, not a controlled substance — so you can only get it legally with a valid prescription. Selling or handing it out without authorization, or importing unapproved “research-chemical” SERMs, is illegal. Enclomiphene sold by compounding pharmacies or “research chemical” vendors is not an FDA-approved finished drug.

For comparison, here’s where some other compounds in this PED-support space sit:

• DNP (2,4-dinitrophenol) is not approved for human consumption — it was declared “not fit for human consumption” in the FDA’s early regulatory era and is sold illegally as a “fat burner.”
• Mesterolone (Proviron) and fluoxymesterone (Halotestin) are anabolic-androgenic steroids and Schedule III controlled substances under the Controlled Substances Act and Anabolic Steroid Control Act (Halotestin’s label carries the “CIII” designation; both are explicitly enumerated as anabolic steroids).
• Insulin and T3 (liothyronine) are prescription drugs, not controlled substances.

In sport, clomiphene (“clomifene”) is prohibited at all times under WADA Section S4 (Hormone and Metabolic Modulators), in the anti-estrogenic SERM subcategory S4.2 — alongside tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, cyclofenil, fulvestrant, and elacestrant. Section S4 also covers aromatase inhibitors (anastrozole, letrozole, exemestane, formestane, and others) and other metabolic modulators including insulins and insulin-mimetics, AMPK activators (AICAR, MOTS-c), and PPARδ agonists. New for 2026: BAM15 was added — WADA classifies it under S4.4.1 as an AMPK-activator example, though mechanistically it is a mitochondrial uncoupler that activates AMPK — and a new aromatase-inhibitor example (α-naphthoflavone / 7,8-benzoflavone) was also added. DNP is banned in sport under S4 as a metabolic modulator; the anabolic steroids mesterolone and fluoxymesterone are prohibited at all times under S1. The 2026 list took effect January 1, 2026.

Safety

Clomiphene / SERMs specifically:

• Vision problems — blurring, spots, flashes, and “scintillating scotomata” (shimmering blind spots in your field of view). The chance goes up with higher total dose and longer use. The FDA label flatly warns these can be prolonged and possibly irreversible, especially with more dose or longer use, and can stick around after you stop the drug; they can make driving or operating machinery unsafe.
• Venous thromboembolism (VTE), meaning dangerous blood clots: the Clomid label itself lists pulmonary embolism (a clot in the lungs) and thrombophlebitis (a clot with vein inflammation) as adverse events, and notes that death from a clot can happen in severe ovarian hyperstimulation syndrome. SERMs as a class carry a known clot risk (DVT/PE), especially in people who already have clotting risk factors.
• Ovarian hyperstimulation syndrome (OHSS) in women — where the ovaries over-respond. It can worsen within 24 hours to days; the severe form includes enlarged ovaries, fluid in the belly (ascites), trouble breathing (dyspnea), low urine output (oliguria), and fluid around the lungs (pleural effusion). A multiple pregnancy (twins or more) is also a risk.
• Other: mood and psychiatric effects, gynecomastia (breast tissue growth) and breast tenderness, hot flashes, and liver concerns with long or high exposure. It should not be used in pregnancy, liver disease, abnormal uterine bleeding, uncontrolled thyroid or adrenal disease, or with a pituitary tumor.

Other compounds in this space, for honest risk context:

• DNP — the most lethal by far. It kills people. It is a mitochondrial uncoupler (it makes cells burn energy as runaway heat) that causes dose-dependent, uncontrolled overheating (core temperatures up to roughly 44 °C / 111 °F), a racing heart (tachycardia), fast breathing (tachypnea), severe metabolic acidosis (dangerously acidic blood), and agitation. There is no antidote; the only treatment is aggressive cooling and fluids. It has a high fatality rate with many documented deaths in dieters and bodybuilders, and the gap between a “fat-loss” amount and a fatal amount is dangerously narrow.
• Insulin (non-diabetic/PED use): risk of severe, possibly fatal low blood sugar (hypoglycemia) — seizures, coma, brain injury, death — which can hit without warning and require emergency glucose.
• Aromatase inhibitors: pushing estrogen too low causes worse cholesterol numbers, faster bone loss / osteoporosis risk, joint pain, and low libido or mood effects.
• T3 (liothyronine): thyroid hormone taken from the outside can cause heart rhythm problems (arrhythmias), a racing heart, atrial fibrillation, and bone loss, and can shut down your own thyroid system (so hypothyroidism can rebound when you stop).

None of this is medical advice.

Bottom line

Clomiphene is a SERM — not a peptide and not a steroid. It is FDA-approved only for triggering ovulation in women; every use in men is off-label. The human evidence that it raises testosterone in men with low testosterone is reasonably strong and consistent — and, unlike testosterone taken from the outside, it tends to keep LH, FSH, and sperm production intact — though long-term safety data are limited and the trials are too small to settle the safety questions. It is a prescription drug in the US, not a controlled substance, but unapproved “research-chemical” SERMs sit outside the regulated system. In sport it is banned at all times. And it carries real risks, including vision problems the FDA label warns can be permanent and a recognized blood-clot risk.

Evidence grade: 10/10 · Established. Strong (8–10) evidence that it raises testosterone in hypogonadal men while preserving fertility; not FDA-approved for men, and long-term safety data remain limited.

Sources

• Clomid (clomiphene citrate) — FDA label via DailyMed
• FDA Drugs@FDA — Clomid label PDF (NDA 016131, 2012 rev.)
• StatPearls — Clomiphene (NCBI Bookshelf, NBK559292)
• Huijben M, et al. 2022 — Clomiphene citrate for men with hypogonadism: systematic review and meta-analysis (Andrology; PMID 34933414; DOI 10.1111/andr.13146)
• Hohl A, et al. 2025 — Clomiphene or enclomiphene citrate for male hypogonadism: SR and meta-analysis of RCTs (Arch Endocrinol Metab 69(5); PMID 41066380; PMCID PMC12510335; DOI 10.20945/2359-4292-2025-0093)
• WADA 2026 Prohibited List
• USADA — Substance Profile: Clomiphene
• USADA — 2026 WADA Prohibited List athlete advisory
• 2,4-Dinitrophenol — Wikipedia